foxo4-dri senolytic human trial 2024 peptide FOXO4-DRI UK Therapeutic targeting of senescent cells

Martinez, S

Considering the results of our in vitro experiments, the anti-RGMa antibody is likely to block the direct and disease-specific interaction between RGM-expressing mature neurons in the GCL and neogenin-expressing neurogenic cells, including NSCs and immature neurons

The most commonly used prolotherapy solution is a hypertonic dextrose solution (typically 1525%) mixed with a local anesthetic such as lidocaine

Primary research: Insulin sensitivity, exercise capacity, metabolic regulation Mechanism: Activates AMPK pathway, regulates folate-methionine metabolism, and modulates nuclear gene expression from the mitochondria Regulatory status: Not FDA-approved